COMPANY RESEARCHAPI development and manufacturing integrate crystallization engineering, salt selection, and polymorph screening.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
| Period | Currency / basis | Revenue | Net profit | Operating cash flow | Report |
|---|---|---|---|---|---|
| FY2025 2025-12-31 | CNY PRC Accounting Standards / consolidated | 6,670,181,013.25 | 1,132,569,775.63 Net income attributable to shareholders of the listed company | 1,407,585,059.7 | Original ↗ |
| 2026Q3 (YTD) 2026-09-30 | CNY PRC Accounting Standards / consolidated | 5,394,933,459.85 | 852,184,750.57 Net income attributable to shareholders of the listed company | 605,316,294.45 | Original ↗ |
Disease tags match recorded text mentions and require program-level verification.
An original October 2026 investor record identifies oral cyclic peptides as a priority business and states that orders have been received. Only manufacturing services are recorded; proprietary drug pipelines are not inferred.
Offers drug product R&D and manufacturing, with publicly listed oral solid, injectable, and biologic formulation development and scale-up services.
The crystallization and process R&D pages disclose solid-form screening, salt selection, polymorph screening, and process optimization.
Building on small-molecule CDMO, the company provides research and manufacturing for peptides, oligonucleotides, antibodies, conjugates, and drug products.
Listed as SZSE 002821 / HKEX 06821; original 2025 annual and 2026Q3 (YTD) reports reviewed.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Oral cyclic peptide CDMO work package | Not disclosed · Not disclosed | 未披露 | Quantitative human results not confirmed in this review |
| Formulation development / contract manufacturing capabilities | Defined by the client project · Defined by the client project | Services / platform | Service pages do not establish human evidence for every project |
| Solid-state R&D capabilities | Determined by the submitted sample and research question · Not applicable; service capability | Services / platform | Not applicable; not a human clinical program |
| Process development and clinical-to-commercial manufacturing | Not applicable (services/platform) · Drug research and manufacturing services for clients | Services / platform | Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Asymchem reported consolidated revenue of RMB5.395 billion, up 16.52%, and attributable net income of RMB852.2 million for the nine months ended September 30, 2026. Attributable net income grew 6.49%, trailing the increase in revenue over the same nine-month period. The quarterly filing is unaudited and covers the year-to-date period.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.